• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic research of cancer stem cell for therapeutic target in cisplatin-resistant ovarian cancer.

Research Project

Project/Area Number 21592149
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionOsaka Medical College

Principal Investigator

TANABE Akiko  大阪医科大学, 医学部, 助教 (70454543)

Co-Investigator(Kenkyū-buntansha) OHMICHI Masahide  大阪医科大学, 医学部, 教授 (10283764)
TERAI Yoshito  大阪医科大学, 医学部, 講師 (90278531)
KANEMURA Masanori  大阪医科大学, 医学部, 講師 (40298782)
SASAKI Hiroshi  大阪医科大学, 医学部, 助教 (80432491)
Project Period (FY) 2009 – 2011
Project Status Completed (Fiscal Year 2011)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords上皮性卵巣癌 / 抗癌剤耐性 / Akt-mTOR-HIF / VEGF / EMT / GPR30 / EGFR / CD24 / snail / E-cadherin / 白金製剤耐性卵巣癌 / 癌幹細胞 / 上皮間葉形質転換
Research Abstract

Epithelial-mesenchymal-transition(EMT) is recently identified as a important step in the invasion, metastasis, and chemo-resistance of cancer. We investigated whether topotecan increase the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. Topotecan significantly inhibited the cisplatin-induced Akt activation, and regulated EMT-related factors in cisplatin-resistant ovarian cancer cell line. Furthermore, G protein-coupled receptor 30 is a 7-transmembrane estrogen receptor that functions alongside traditional estrogen receptors to regulate cellular responses to estrogen. In our studies suggested that GPR30 expression is linked to EMT phenotype, aggressive proliferation, and multiple drug resistance. Immunohistochemical examination revealed that expression of both GPR30 and EGFR contributes lower survival rates in epithelial ovarian cancer.

Report

(4 results)
  • 2011 Annual Research Report   Final Research Report ( PDF )
  • 2010 Annual Research Report
  • 2009 Annual Research Report
  • Research Products

    (12 results)

All 2011 2010 2009

All Journal Article (5 results) (of which Peer Reviewed: 5 results) Presentation (7 results)

  • [Journal Article] Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer2011

    • Author(s)
      Tanaka Y, Tanabe A
    • Journal Title

      Cancer Biology & Therapy

      Volume: 11巻 Pages: 50-57

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer2011

    • Author(s)
      Tanaka Y, Tanabe A, et al
    • Journal Title

      Cancer Biol.Ther.

      Volume: 11 Pages: 50-57

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers2010

    • Author(s)
      Tsunetoh S, Tanabe A
    • Journal Title

      Cancer Biology & Therapy

      Volume: 10巻 Pages: 1137-1146

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.2010

    • Author(s)
      Tsunetoh S, Tanabe A, Ohmichi M., et al
    • Journal Title

      Cancer Biology & Therapy

      Volume: 10 Pages: 1137-1146

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.2010

    • Author(s)
      Tanaka Y, Tanabe A, Ohmichi M., et al
    • Journal Title

      Cancer Biology & Therapy

      Volume: 11 Pages: 50-57

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Presentation] 卵巣癌におけるエストロゲン受容体GPR30およびER/PRの発現と臨床病理学的意義2011

    • Author(s)
      藤原聡枝、田辺晃子
    • Organizer
      第63回日本産婦人科学会学術講演会
    • Place of Presentation
      大阪
    • Related Report
      2011 Annual Research Report 2011 Final Research Report
  • [Presentation] 婦人科癌とEMT2011

    • Author(s)
      寺井義人、田辺晃子
    • Organizer
      第50回日本婦人科腫瘍学会学術集会
    • Place of Presentation
      北海道
    • Related Report
      2011 Annual Research Report 2011 Final Research Report
  • [Presentation] 卵巣癌におけるエストロゲン受容体GPR30およびER/PRの発現と臨床病理学的意義2011

    • Author(s)
      藤原聡枝、田辺晃子, et al
    • Organizer
      第52回日本臨床細胞学会総会
    • Place of Presentation
      福岡
    • Related Report
      2011 Annual Research Report
  • [Presentation] 卵巣癌におけるGPR30とEGFRの免疫組織化学的検討2010

    • Author(s)
      藤原聡枝、田辺晃子、大道正英
    • Organizer
      第62回日本産婦人科学会学術講演会
    • Place of Presentation
      東京国際フォーラム
    • Year and Date
      2010-04-23
    • Related Report
      2010 Annual Research Report
  • [Presentation] 卵巣癌におけるEGFR遺伝子変異とその下流シグナル分子の発現解析2010

    • Author(s)
      田中良道、田辺晃子、大道正英
    • Organizer
      第62回日本産婦人科学会学術講演会
    • Place of Presentation
      東京国際フォーラム
    • Year and Date
      2010-04-23
    • Related Report
      2010 Annual Research Report
  • [Presentation] 卵巣癌におけるGPR30の免疫組織化学的検討2010

    • Author(s)
      藤原聡枝、田辺晃子、大道正英
    • Organizer
      第48回日本癌治療学会学術集会
    • Place of Presentation
      国立京都国際会館
    • Related Report
      2010 Annual Research Report
  • [Presentation] 卵巣癌におけるGPR30の免疫組織化学的検討2009

    • Author(s)
      藤岡聡枝, 田辺晃子, 大道正英
    • Organizer
      第47回日本癌治療学会学術集会
    • Place of Presentation
      パシフィコ横浜(神奈川)
    • Year and Date
      2009-10-22
    • Related Report
      2009 Annual Research Report

URL: 

Published: 2009-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi